The Effects of Colistin on Imipenem MICs in OXA-48 Producing Klebsiella pneumoniae Isolates: An In Vitro Study

Basit Öğe Kaydı
dc.authoridDuman, Yucel/0000-0002-9090-2096;
dc.authorwosidDuman, Yucel/AAU-6221-2020
dc.authorwosidYAKUPOGULLARI, YUSUF/F-3966-2011
dc.contributor.authorDuman, Yucel
dc.contributor.authorTekerekoglu, Mehmet Sait
dc.contributor.authorKuzucu, Cigdem
dc.contributor.authorYakupogullari, Yusuf
dc.date.accessioned2024-08-04T20:50:28Z
dc.date.available2024-08-04T20:50:28Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction: A new approach to carbapenem resistance-K. pneumoniae infections is to use combination drug therapies. However, little data are available about the effectiveness of the in vitro carbapenem plus colistin combination against oxacillinase-48 (OXA-48) producing K. pneumoniae. Therefore, the aim of this study is to assess the potential synergistic activity of imipenem plus colistin in OXA-48-producing K. pneumoniae strains and investigate the changes in the imipenem minimal inhibitory concentrations (MICs) to varying MICs of colistin. Materials and Methods: Carbapenem and colistin resistance (CoIR) genes were investigated by polymerase chain reaction. In the first stage, synergistic properties were determined by the checkerboard combination method. In the second step, at varying colistin concentrations, changes in the imipenem MICs were investigated. Results: Colistin MIC50 2 mu g/ml, MIC90 16 mu g/ml, and imipenem MIC50 32 mu g/ml, MIC90 128 mu g/ml were found, respectively. According to the fractional inhibitor concentration (FIC) formula, 62.2% of the isolates were synergistic, and 37.8% were indifference. When the colistin was fixed at 0.125 mu g/ml, 0.25 mu g/ml, 0.5 mu g/ml, 1 mu g/ml, and 2 mu g/ml, respectively. Significant decreases were observed in the imipenem Mies, especially of colistin-sensitive isolates. However, imipenem MICs of CoIR isolates did not decrease to susceptible levels. Conclusion: This information will facilitate the design of antibiotic regimens that are more suitable for treating infections due to such pathogens producing OXA-48 and prolong these antibiotics' efficacy. Further in vitro research is required to determine which treatment combination is best and its optimal use as combination therapy to treat these infections.en_US
dc.identifier.doi10.4274/mjima.galenos.2020.2021.2
dc.identifier.issn2147-673X
dc.identifier.scopus2-s2.0-85111555243en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.urihttps://doi.org/10.4274/mjima.galenos.2020.2021.2
dc.identifier.urihttps://hdl.handle.net/11616/100083
dc.identifier.volume10en_US
dc.identifier.wosWOS:000632653300001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofMediterranean Journal of Infection Microbes and Antimicrobialsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectColistinen_US
dc.subjectimipenemen_US
dc.subjectcombinationen_US
dc.subjectKlebsiella pneumoniaeen_US
dc.subjectOXA-48en_US
dc.titleThe Effects of Colistin on Imipenem MICs in OXA-48 Producing Klebsiella pneumoniae Isolates: An In Vitro Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu